# High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)

> **NCT04126460** · PHASE2 · UNKNOWN · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 41 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04126460
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-10
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2019-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04126460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04126460, "High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04126460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*